Abstract Although zinc transporters were shown to play roles in the development of prostate, bladder, and renal cancer, no study has evaluated the genetic variants in zinc transporter genes with risk of urological cancers. A candidate gene association study using genome-wide association study (GWAS) datasets was conducted for variants in 24 zinc transporter genes. Genotypes were analyzed using logistic regression models adjusted for covariates. The function of identified variants was assessed by using the Encyclopedia of DNA Elements (ENCODE). We further evaluated tumors for somatic change of the implicated gene(s) and the associations between identified variants and patient survival from data in The Cancer Genome Atlas (TCGA). A ZIP11 variant, rs8081059, was significantly associated with increased risk of renal cell carcinoma (odds ratios (OR)=1.28, 95 % confidence intervals (CI) (1.13-1.45), p=0.049). No zinc transporter variants were associated with prostate cancer risk. Four variants within ZIP11 were significantly associated with bladder cancer risk: rs11871756 (OR=1.43, 95 % CI (1.24-1.63), p=0.0002), rs11077654 (OR= 0.76, 95 % CI (0.68-0.85), p=0.001), rs9913017 (OR=0.76, 95 % CI (0.68-0.85), p=0.002), and rs4969054 (OR=0.78, 95 % CI (0.69-0.88), p=0.02); the three protective variants were co-located and highly correlated. These variants were located within predicted transcribed or enhancer regions. Among the 253 bladder cancer patients in TCGA, two had tumors that contained deleterious missense mutations in ZIP11. Moreover, rs11077654 was significantly associated with survival of bladder cancer patients (p=0.046).
Introduction
Zinc is a mineral that is vital for maintaining human health [1] . Zinc ion transporters are critical in sustaining the tightly regulated concentration of zinc in human cells necessary for normal cellular functions [2, 3] . Interestingly, studies have demonstrated that the imbalance of zinc ions and dysfunction of zinc transporters have implications for development of urological cancers [4, 5] . For example, abnormal expression or function of zinc transporters ZIP1, ZIP4, ZIP6, ZNT4, and ZNT7, as well as the imbalance in zinc ions, plays important roles in prostate cancer development in vitro and in animal models [6] [7] [8] [9] [10] [11] [12] [13] [14] . Moreover, ZIP10 and ZNT1 are important in maintaining renal zinc reabsorption, and the zinc imbalance in renal cells is linked to renal cell carcinoma (RCC) development [3, [14] [15] [16] [17] [18] [19] [20] . Similarly, zinc imbalance is reported to be associated with the risk of bladder cancer [21] [22] [23] [24] [25] . Despite these demonstrated links between zinc and urologic carcinogenesis, to date, there have been no systematic studies of the role of genetic variation in zinc transporter genes and risk of urologic cancers. Such a study could suggest a role for identified susceptibility variants in the etiology of the relevant cancer. Moreover, therapeutic strategies based on implicated targets could potentially be developed.
Motivated by this, we hypothesized that people who carry specific genetic variants in zinc transporter genes are at increased risk of developing urologic cancers. To test this hypothesis, we conducted a candidate gene association study [26, 27] of 24 zinc transporter genes (ZNT1-10, ZIP1-14) to evaluate whether any variants confer susceptibility to three primary urological cancers (prostate adenocarcinoma, transitional cell carcinoma of the bladder, and RCC). Additionally, to investigate identified variants/genes, we used available sequencing, genotyping, and survival data from The Cancer Genome Atlas (TCGA) [28] focusing on cancers of interest to evaluate additional evidence.
Materials and methods
Three genome-wide association study (GWAS) datasets of urological cancers (prostate adenocarcinoma, transitional cell carcinoma of the bladder, and RCC) were downloaded from the database of Genotypes and Phenotypes (dbGaP) in August 2011:
(1) Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer GWAS [29] Within each cancer type, we combined the separate datasets into a single dataset to increase statistical power for each cancer, respectively. We tested for 1143 variants, 704 variants, and 149 variants in the bladder cancer dataset, RCC dataset, and prostate cancer dataset, respectively. Unconditional multivariable logistic regression models with an additive SNP effect were employed [32] . For the prostate cancer data, we adjusted for age and family history of prostate cancer. For the bladder cancer data, we adjusted for age and sex. Given the well-known gender disparity in RCC (2:1 male to female ratio), in our analysis of the RCC data, we adjusted for sex. In all analyses, odds ratios (OR) and 95 % confidence intervals (CI) were computed using Plink (http://pngu.mgh. harvard.edu/~purcell/plink/) [33] .
To limit the false-positive results as well as to account for multiple testing and correlations between genetic variants, we computed a family-wise corrected p value using the maxT permutation tests in plink [34] using 5000 replicates. To determine whether any of the significant variants were within the same linkage disequilibrium (LD) block, we used the 1000 Genomes Project [35] browser (http://browser.1000genomes. org/Homo_sapiens/UserData/Haploview). Genetic information of Caucasian population groups (CEU, FIN, GBR, IBS, and TSI) in the most updated data of 1000 Genomes Project (up to April 2014) was used. We further used Haploview [36] to plot the linkage disequilibrium among significant variants.
To investigate the potential functionality of any suggested variants from the association analyses, we performed in silico analysis with publicly available data. We used the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgTracks? db=hg19) on January 14, 2015, to evaluate the function of both transcribed and non-transcribed variants. The latter was done by comparing the position of significant SNPs to the Encyclopedia of DNA Elements (ENCODE) annotation. In particular, Genome Segmentation by Combined Segway+ ChromHMM (GSCSC) [37, 38] track was used to detect whether variants were located in any of the predicted functional regions of the genome. Briefly, computational analysis of chromatin state segmentation at a 200 base pair resolution generated 15 states, ranging from state 1 (active promoter) to state 15 (repetitive/copy number variation) [39] . States 4-7 represent categories of enhancer (from strong to weak/poised [40] ), and states 9-11 represent categories of transcription regions (transcriptional transition, elongation, and weak transcribed region, respectively). Publicly available data on several cell lines of human origin were used to explore function prediction, including K562 (erythrocytic leukemia cells), HepG2 (hepatocellular carcinoma cells), H1-hESC (embryonic stem cells), GM12878 (B-lymphoblastoid cells), HSMM (human skeletal muscle myoblasts), NHLF (normal lung fibroblasts), HUVEC (umbilical vein endothelial cells), HMEC (mammary epithelial cells), and NHEK (normal epidermal keratinocytes). An analogous and productive interrogation approach with ENCODE performed on SNPs in breast cancer has been previously reported [41] .
To determine whether any genetic change within identified gene(s) were functional at the somatic/tumor level of patients, we analyzed available data from TCGA. The detailed sequencing procedures and analytic processes have been described previously [42] . The somatic level genetic change of 253 bladder cancer patients and 506 RCC patients was retrieved through the TCGA data portal on November 16, 2014 (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). We focused on the GWAS-implicated gene(s) to determine the existence and prevalence of somatic variation in the patients reported by TCGA.
To determine whether any of the identified variants may be associated with survival of cancer patients, we conducted multivariable linear regression analysis employing available data from TCGA. Variables that may influence disease survival (age, gender, race, smoking status, and tumor grade) were adjusted for in the model.
Results

Transitional cell carcinoma of the bladder
Fifteen variants demonstrated association with bladder cancer risk at significance levels of p≤0.002. Among these, four variants within ZIP11 were significantly associated with bladder cancer risk after correcting for multiple comparisons (Table 1) . One variant, rs11871756, was associated with increased risk of bladder cancer (OR = 1.43, 95 % CI (1.24-1.63), p = 0.0002). Three variants were associated with a reduced risk of bladder cancer: rs11077654 (OR=0.76, 95 % CI (0.68-0.85), p =0.001), rs9913017 (OR =0.76, 95 % CI (0.68-0.85), p=0.002), and rs4969054 (OR=0.78, 95 % CI (0.69-0.88), p=0.02); further LD analysis revealed that these three variants are highly correlated (Fig. 1) and are within the same LD block in chr17:71006408-71021645 (build 37).
Focusing on common SNPs (minor allele frequency, MAF≥0.10) in the region within which the three protective variants are located, we observed that risk estimates of these variants were mostly protective (OR<1) among the SNPs closely proximal to the three variants ( Table 2 and Fig. 1) . In silico functional analysis found that the three protective variants of interest were located in a block that is a weak/poised enhancer region according t o the ENCODE a nnotation. Specifically, rs11077654 is located within a weak/poised enhancer region by cell lines K562 and HepG2 and a weakly transcribed region by cell lines H1-hESC, GM12878, and HSMM. Variant rs9913017 is located within a weakly transcribed region by cell lines H1-hESC, GM12878, K562, HepG2, HSMM, and NHLF. Variant rs4969054 is located within a weak/poised enhancer region by cell lines GM12878 and K562 and a weakly transcribed region by cell lines H1-hESC, HepG2 HSMM, and NHLF. The risk variant rs11871756 was predicted to be in a weakly transcribed region by cell lines GM12878 and HepG2 and a weak/poised enhancer region by cell lines K562 and HUVEC.
After evaluating somatic mutations among 253 bladder cancer patients in the TCGA data, we found two patient tumors that contained missense mutations (chr17:70643734_C/ A and chr17:71027826_G/A (build 37)). Further in silico analysis of functional prediction using both SIFT and PolyPhen-2 [43] revealed that these two mutations are predicted to be deleterious.
Two of the suggested variants (rs11871756 and rs11077654) were included in the genotyping platform of the TCGA bladder cancer patients and were tested for their associations with patients' survival using available data on 95 patients, after adjusting for age, gender, race, smoking status, and tumor grade. The SNP rs11871756 did not demonstrate a significant effect on survival. However, rs11077654 was significantly associated with survival by genotype (p=0.046). Specifically, patients with genotype AA had an average survival of 407 days, patients with genotype CA survived 556 days, and patients with genotype CC survived 755 days.
Renal cell carcinoma (RCC)
Seven variants in ZIP11 were associated with RCC risk at significance level of p≤0.002. Further permutation testing demonstrated that rs8081059 was associated with RCC risk after accounting for multiple comparisons (OR=1.28, 95 % CI (1.13-1.45), p=0.049) ( Table 1 ). In silico functional analysis suggested it to be within a predicted transcribed region by the GSCSC track and transcriptional transition or elongation by cell line GM12878 and weakly transcribed region by cell lines K562, HepG2, HUVEC, HMEC, HSMM, NHEK, and NHLF. Furthermore, this variant was in an open chromatin region according to DNAse I hypersensitivity cluster in 125 cell types and in the intron proximal to the splice site.
Evaluation of ZIP11 using TCGA data among RCC patients did not reveal any somatic mutations. The identified variant rs8081059 was not captured in the genotyping platform of TCGA patients, thus precluding further exploration of this variant with available data.
Prostate adenocarcinoma
There were no significant associations between any variants and the risk of prostate cancer. [35] b Multiple comparisons were accounted for by permutation tests using 5000 replicates [44] . Among them, 74,000 were expected to develop urinary bladder cancer and 61,560 were expected to develop kidney cancer [44] . In China, prostate cancer was reported in 2010 to be the 8th most common cancer in urban areas [45] . It is thus critical to better understand the etiology of urological cancers to decrease their health burden. While evidence for a role of zinc in urologic carcinogenesis has been reported at the cellular and animal model levels [21] [22] [23] [24] [25] , we report the first examination of the role of germline genetic variation in zinc transporter genes as modulators of urologic cancer risk in human subjects. Moreover, this is the first report of an association of ZIP11 variants with development of RCC and transitional carcinoma of the bladder. Although suggested by basic laboratory research [6] [7] [8] [9] [10] [11] [12] , variants in several other zinc transporter genes were not associated with urological cancer risk in our study. One explanation is that the variants evaluated in this study were restricted to those SNPs in the genotyping platforms, and causal mutations/variants affecting gene function were not well captured. Plausible genetic factors beyond SNPs, such as epigenetic factors or possible interactions of ZIP11 variants with known environmental risk factors for RCC (e.g., smoking, obesity, etc.), could not be assessed because the available data were limited. If our findings are confirmed by independent studies, further work, including targeted sequencing of ZIP11, may be warranted to identify additional predisposition variants or mutations for bladder cancer and RCC. ZIP11 was recently demonstrated to be a zinc importer for cells [46] . Knockdown of this gene can decrease cellular zinc concentrations and metallothionein levels. Though its relationship with development of human cancers is previously unknown, our study suggests that several genetic variants of this gene, which are potentially functional, may modulate risk of bladder cancer and renal cell carcinoma. Further research for clarifying role of ZIP11 in development of these two cancers, as well as examination of exact roles of identified genetic variants, are warranted.
Non-coding portions of the human genome have long been suspected to be biologically relevant and important, although it was not until recently through the ENCODE project [47] that a comprehensive appreciation and understanding of the potential role of non-coding regions became possible. Located within traditional designated Bnon-coding^regions, the variants in our study found to be associated with risk of bladder, and renal cancers are within predicted functional regions (i.e., transcribed or enhancer regions) from the ENCODE annotation. In silico prediction involving knowledge of both exon regions and non-coding regions (using the ENCODE segmentation) can be helpful in linking disease-associated variants identified through epidemiological studies to their plausible functionality and ultimately to etiology of human diseases [41] . Knowledge generated through this process can be used to guide further research for clarifying the mechanism for disease development.
One limitation of this study is that we could not fully adjust for all known risk factors of studied tumors in the association analyses, due to the unavailability of relevant information. However, evidence from additional analyses, especially the identified somatic mutations in bladder cancer patients as well as the association with survival of bladder cancer patients, supports the plausibility of ZIP11's important role. Future association studies accounting for all risk factors are warranted to validate our findings.
